
Payers
Latest Content
Latest Videos

Shorts
Podcasts
More News

Earlier Alzheimer disease detection is outpacing specialist capacity and may widen gaps for underserved patients, Cleveland experts say.

Eosinophil thresholds and documentation rules shape COPD biologic access. At ERS 2026, experts discussed biomarkers, delays, and multidisciplinary care.

Six studies found liver transplant disparities by insurance, region, ethnicity, and sex, plus links between unmet social needs and frailty in cirrhosis.

Most patients with CLL/SLL who discontinued a first-line BTK inhibitor did not start second-line therapy, and older age was linked to worse outcomes.

With the midterms behind them, health system leaders say coverage losses, thin margins, and payer fights are coming no matter who controls Congress.

Michael Mina, MD, PhD, of Invivyd, on measles antibody VMS063, immune amnesia, and what RSV antibody uptake signals for payers.

The Community Oncology Alliance said the final 2027 Medicare payment rules address longstanding gaps between hospital and community practice reimbursement, but it urged Congress to stop another physician pay cut and to fix how the Inflation Reduction Act will pay practices for Part B drugs.

The planned separation would keep Aetna, CVS Caremark, and Oak Street Health together and move roughly 9000 drugstores into a new CVS Pharmacy.

Pharmacy leaders from academic and community practices discuss the infrastructure, partnerships, and payer strategies for outpatient access.

Pharmacists outline new oncologic therapeutics, from pancreatic cancer to myeloma, and what high prices and crowded markets mean for payers.

A home-based oncology model using clear bagging is transformational for practices, protecting Medicare reimbursement and provider control, while lowering costs for patients, providers and payers

Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.

An analysis of AccessHope case reviews found that experts recommended changes in more than 80% of cases. About half were implemented, saving a median of $18,636 per case.

How Capitation and Crowded EDs Shape Who Gets Access to Menin Inhibitors in AML
At an AJMC® Stakeholder Interchange in Los Angeles, leukemia specialists described a region where hospital formularies push menin inhibitor starts into the clinic, emergency department (ED) physicians may not recognize differentiation syndrome, and capitated insurance contracts steer some patients with acute myeloid leukemia away from academic centers.

At AMCP Nexus 2026, payers said evidence, differentiation, and delivery now matter as much as FDA approval.

James D. Chambers, PhD, MPharm, MSc, discusses US biosimilar adoption and opportunities to expand patient access and lower treatment costs.

A poster at the ASCO Quality Care Symposium describes how a value-based care partnership used prior authorization data and pharmacist workflows to move eligible patients off flat dosing of pembrolizumab.



















